EMMAC Life Sciences Ltd, the European independent medical cannabis company, has announced the acquisition of Rokshaw Limited, a UK MHRA approved specials manufacturer.
The acquisition brings immediate revenues to EMMAC and enables the company to import medical cannabis into the UK to meet the growing demands of the market, led by regulatory change, for premium medical cannabis product.
Founded in 2012, Sunderland-based Rokshaw is a leading UK laboratory, manufacturing a wide range of Specials bespoke to patient requirements in an EU GMP environment to ensure that patients across the UK receive the highest quality products. Rokshaw has already manufactured more than 6,000 formulations for over 2,000 pharmacies and hospitals across the UK.
Antonio Costanzo, CEO of EMMAC, commented: “We are delighted to announce the acquisition of Rokshaw today. This investment not only brings with it an immediate revenue stream but also provides EMMAC instant access to the UK medical cannabis market with the opportunity to grow the existing 45 people-strong team into a centre of medical cannabis excellence for the UK. Joining us are the two founders of Rokshaw, Jonathan and Richard Hodgson, who have significant and relevant experience of working in this highly regulated industry as well as a proven track record of delivering high quality product.”
Jonathan and Richard Hodgson, co-founders of Rokshaw, said: “We are really pleased to have joined EMMAC at this exciting stage of its corporate development as we share its vision of becoming the leading European independent medical cannabis company. We are confident that the team here at Rokshaw can play an important role in EMMAC achieving its goal through the provision of high-quality product and services to patients across the UK, and by unlocking the potential for the medical cannabis market to meet growing clinician and patient demand.”